Government-Owned Inventions; Availability for Licensing and Collaboration, 65183 [2023-20479]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 182 / Thursday, September 21, 2023 / Notices
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: October 27, 2023.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G13A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mairi Noverr, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activitie,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G13A, Rockville, MD
20852, (240) 747–7530, mairi.noverr@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 15, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20421 Filed 9–20–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing and
Collaboration
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention described
below presents an advancement
concerning osteoclast fusion; osteoclasts
are responsible for human skeletal
remodeling and their dysfunction is a
key factor for both rare and common
bone diseases. The invention covers
methods for modulating osteoclast
fusion and bone resorption through the
Lupus autoantigen (La) protein. The
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development (NICHD), National
Institutes of Health, has conducted
conceptual in-vitro studies and is now
seeking potential licensees and
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:11 Sep 20, 2023
Jkt 259001
collaborators for further development
and advancement.
ADDRESSES: Inquiries relating to this
licensing and collaboration opportunity
should be directed to: Heather Gunas,
JD, MPH, Senior Technology Transfer
Manager, National Cancer Institute
(NCI) Technology Transfer Center, 9609
Medical Center Drive, Room 1E446,
Rockville, MD 20850 (for overnight
mail) or Bethesda, MD 20892 (for
regular mail), Telephone: (240) 276–
5530; Facsimile: (240) 276–5504; Email:
gunash@mail.nih.gov. A Confidential
Disclosure Agreement will be required
to receive copies of unpublished
information regarding this invention.
SUPPLEMENTARY INFORMATION: The
following and all continuing U.S. and
foreign patents/patent applications
thereof are available for licensing: PCT
Application No. PCT/US22/018639,
filed March 3, 2022, and entitled ‘‘La
protein as a novel regulator of
osteoclastogenesis.’’ The Lupus
autoantigen (La) protein is a master
regulator of osteoclasts. The technology
involves a novel mechanism for precise
regulation of osteoclastogenesis through
the manipulation of surface La protein.
The ability of osteoclasts to remodel
bone can be modulated by: (1)
administering an effective amount of La
protein or (2) administering an agent
that modulates La protein expression or
activity. Current solutions for bone
diseases are usually broad-spectrum
treatments that either coat the skeletal
system or inhibit osteoclast
development and these approaches can
result in off-target side effects. This
technology’s approach to regulating
osteoclast fusion and osteoclastogenesis
by targeting the La protein should
bypass many side effects. The
technology has been supported by
conceptual in-vitro data and lead
optimization is ongoing; further
research and development are required
to advance it towards disease-specific
preclinical and clinical stages.
Potential Commercial Application:
Treatment of common and rare bone
diseases, including osteoporosis, Paget’s
disease of bone, fibrous dysplasia,
rheumatoid arthritis, osteopetrosis,
osteomyelitis, or metastatic bone
disease.
Development Stage: In-vitro study
completed and lead optimization
ongoing.
Dated: September 18, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2023–20479 Filed 9–20–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
65183
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Social and Environmental Determinants of
Health Study Section.
Date: October 18–19, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ananya Paria, DHSC,
MPH, MS, Scientific Review Officer, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1007H,
Bethesda, MD 20892, (301) 827–6513,
pariaa@mail.nih.gov.
Name of Committee: Digestive, Kidney and
Urological Systems Integrated Review Group;
Digestive and Nutrient Physiology and
Diseases Study Section.
Date: October 19–20, 2023.
Time: 9:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Aster Juan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20817, 301–435–5000, juana2@mail.nih.gov.
Name of Committee: Endocrinology,
Metabolism, Nutrition and Reproductive
Sciences Integrated Review Group; Human
Studies of Diabetes and Obesity Study
Section.
Date: October 19–20, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Hui Chen, MD, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
E:\FR\FM\21SEN1.SGM
21SEN1
]]>Agencies
[Federal Register Volume 88, Number 182 (Thursday, September 21, 2023)]
[Notices]
[Page 65183]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-20479]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing and
Collaboration
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention described below presents an advancement
concerning osteoclast fusion; osteoclasts are responsible for human
skeletal remodeling and their dysfunction is a key factor for both rare
and common bone diseases. The invention covers methods for modulating
osteoclast fusion and bone resorption through the Lupus autoantigen
(La) protein. The Eunice Kennedy Shriver National Institute of Child
Health and Human Development (NICHD), National Institutes of Health,
has conducted conceptual in-vitro studies and is now seeking potential
licensees and collaborators for further development and advancement.
ADDRESSES: Inquiries relating to this licensing and collaboration
opportunity should be directed to: Heather Gunas, JD, MPH, Senior
Technology Transfer Manager, National Cancer Institute (NCI) Technology
Transfer Center, 9609 Medical Center Drive, Room 1E446, Rockville, MD
20850 (for overnight mail) or Bethesda, MD 20892 (for regular mail),
Telephone: (240) 276-5530; Facsimile: (240) 276-5504; Email:
[email protected]. A Confidential Disclosure Agreement will be
required to receive copies of unpublished information regarding this
invention.
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are available for
licensing: PCT Application No. PCT/US22/018639, filed March 3, 2022,
and entitled ``La protein as a novel regulator of osteoclastogenesis.''
The Lupus autoantigen (La) protein is a master regulator of
osteoclasts. The technology involves a novel mechanism for precise
regulation of osteoclastogenesis through the manipulation of surface La
protein. The ability of osteoclasts to remodel bone can be modulated
by: (1) administering an effective amount of La protein or (2)
administering an agent that modulates La protein expression or
activity. Current solutions for bone diseases are usually broad-
spectrum treatments that either coat the skeletal system or inhibit
osteoclast development and these approaches can result in off-target
side effects. This technology's approach to regulating osteoclast
fusion and osteoclastogenesis by targeting the La protein should bypass
many side effects. The technology has been supported by conceptual in-
vitro data and lead optimization is ongoing; further research and
development are required to advance it towards disease-specific
preclinical and clinical stages.
Potential Commercial Application: Treatment of common and rare bone
diseases, including osteoporosis, Paget's disease of bone, fibrous
dysplasia, rheumatoid arthritis, osteopetrosis, osteomyelitis, or
metastatic bone disease.
Development Stage: In-vitro study completed and lead optimization
ongoing.
Dated: September 18, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2023-20479 Filed 9-20-23; 8:45 am]
BILLING CODE 4140-01-P
